A lung transplant can be lifesaving for carefully selected people with irreversible end-stage lung disease. That fact raises an understandable question for patients facing severe respiratory symptoms from malignant pleural mesothelioma: if the disease affects the chest and compromises breathing, can the damaged lungs simply be replaced?
In most cases, the answer is no.
Lung transplantation is not a standard treatment for active malignant pleural mesothelioma. Current lung transplant candidate-selection guidance identifies malignancy with a high risk of recurrence or cancer-related death as an absolute contraindication to transplantation. Mesothelioma treatment instead centers on cancer-directed therapies such as surgery in carefully selected patients, systemic therapy, immunotherapy, radiation therapy, and symptom-directed care.
The distinction matters because mesothelioma is not simply a disease of damaged lung tissue. Understanding where this cancer begins explains why replacing a lung is very different from treating mesothelioma.
Can a Mesothelioma Patient Get a Lung Transplant?
For a patient with active malignant mesothelioma, conventional lung transplantation is generally not considered an established treatment option.
The main problem is cancer recurrence. Lung transplant recipients must take immunosuppressive medications to prevent their immune system from attacking the donor organ. This lifelong suppression of immune activity complicates transplantation in people with active or high-risk malignancies.
International lung transplant candidate-selection guidance states that malignancy with a high risk of recurrence or cancer-related death is an absolute contraindication. Evaluation of someone with a previous cancer history is individualized and requires assessment of recurrence risk and an appropriate cancer-free interval when applicable.
This does not mean that transplant medicine never intersects with oncology. Highly specialized and investigational approaches have been explored for certain carefully selected, lung-limited malignancies. These exceptional programs should not be interpreted as evidence that lung transplantation is an established treatment for malignant pleural mesothelioma.
For someone with mesothelioma, the relevant question is therefore usually not, “How do I get on a lung transplant list?” It is, “Which mesothelioma treatments are appropriate for my disease location, stage, tumor characteristics, overall health, and treatment goals?”
Why Replacing the Lung Does Not Necessarily Remove Mesothelioma
Malignant pleural mesothelioma develops in the pleura, the thin tissue surrounding the lungs and lining the inside of the chest.
That location is crucial.
A disease such as idiopathic pulmonary fibrosis primarily damages lung tissue. In advanced cases, transplantation may replace the irreversibly damaged organ. The National Heart, Lung, and Blood Institute identifies lung transplantation as a possible option for some people with serious idiopathic pulmonary fibrosis when appropriate.
Pleural mesothelioma behaves differently. The tumor can grow along pleural surfaces and may involve nearby structures. Removing and replacing lung tissue alone does not necessarily remove all cancer-containing tissue.
This is also why lung transplantation should not be confused with major cancer operations used in selected patients with resectable pleural mesothelioma. The National Cancer Institute lists surgery among the treatment modalities for mesothelioma, alongside radiation therapy, chemotherapy, immunotherapy, and targeted therapy. The exact role of surgery depends on disease characteristics and multidisciplinary evaluation.
Lung Transplant vs. Mesothelioma Surgery
The original terminology surrounding these operations can be confusing because both may involve major surgery inside the chest.
A lung transplant replaces one or both diseased lungs with donor lungs. MedlinePlus defines lung transplantation as surgery that replaces one or both diseased lungs with healthy lungs from a human donor.
A heart-lung transplant is a different operation. It replaces both the heart and lungs. It is not the routine method used for an isolated lung transplant.
Mesothelioma surgery, meanwhile, is cancer-directed surgery rather than organ transplantation. Depending on the individual case and treatment center, surgical strategies may involve removing visible tumor and affected pleural tissue, sometimes as part of a multimodality treatment plan.
These procedures have different purposes:
- Lung transplantation treats irreversible end-stage organ failure.
- Heart-lung transplantation treats selected severe diseases affecting both the heart and lungs.
- Mesothelioma surgery attempts to manage cancer in appropriately selected patients.
A patient should not assume that being medically eligible for major thoracic surgery means being eligible for transplantation. The selection criteria and therapeutic goals are fundamentally different.
How Is a Lung Transplant Performed?
Lung transplantation is performed under general anesthesia. Depending on the disease and clinical circumstances, a patient may receive a single-lung or double-lung transplant.
During transplantation, the surgical team removes the diseased lung and connects the donor lung to the recipient’s airway and the blood vessels carrying blood to and from the lung. In a double-lung transplant, the diseased lungs are generally replaced sequentially.
Some patients require cardiopulmonary support during surgery, but the recipient’s heart is not routinely removed during a lung transplant. That description applies to a heart-lung transplant, which is a separate procedure.
The distinction corrects an important misconception: a bypass or extracorporeal support system may temporarily support circulation and oxygenation during certain transplant operations, but using such support does not mean the patient’s heart is being replaced.
Once the donor lung is positioned, surgeons establish the necessary airway and vascular connections. The surgical and critical care teams then monitor oxygenation, blood flow, heart function, bleeding, and the early function of the transplanted organ.
Who Is Usually Considered for Lung Transplantation?
Lung transplantation is generally considered for selected people with advanced, life-threatening lung disease when other appropriate treatments are no longer sufficient.
Conditions that can lead to transplant evaluation include certain cases of:
- interstitial lung disease and pulmonary fibrosis;
- chronic obstructive pulmonary disease;
- cystic fibrosis;
- pulmonary arterial hypertension;
- bronchiectasis; and
- other forms of irreversible end-stage lung disease.
Evaluation is much broader than measuring lung function alone. A transplant center assesses whether the potential benefit of transplantation is likely to outweigh the considerable short- and long-term risks.
The evaluation may involve transplant pulmonologists, thoracic surgeons, transplant coordinators, cardiologists, infectious disease specialists, pharmacists, dietitians, rehabilitation professionals, social workers, and other specialists.
Candidate-selection guidance considers multiple factors, including cancer history, kidney and liver function, cardiovascular disease, active infections, functional status, ability to participate in rehabilitation, treatment adherence, and psychosocial circumstances relevant to safe transplant care.
For a person with active mesothelioma, however, the cancer itself is the central obstacle to routine transplant candidacy.
What Happens During Transplant Evaluation and Waiting?
A referral to a transplant center does not automatically lead to placement on the transplant waiting list.
The evaluation process determines whether transplantation is medically appropriate and whether the candidate can safely undergo the operation and demanding post-transplant care. Testing varies by center and patient but can include lung function testing, blood tests, imaging, cardiac evaluation, infection screening, cancer screening, nutritional assessment, and rehabilitation evaluation.
If a patient is accepted and listed, the waiting period is unpredictable. Donor matching and organ allocation depend on multiple clinical and logistical factors rather than a simple first-come, first-served queue.
Patients awaiting transplantation must remain reachable and medically prepared because a suitable organ offer may arise unexpectedly. At the same time, their health is continually reassessed because clinical status can change while they wait.
Major Risks of Lung Transplantation
Lung transplantation can extend survival and improve quality of life for appropriately selected patients with end-stage lung disease, but it carries substantial risks.
The two defining long-term challenges are rejection and infection. NHLBI notes that these are major complications of lung transplantation, and recipients need lifelong medication to reduce the risk of rejection.
Other complications may include:
- primary graft dysfunction, in which the transplanted lung develops severe early dysfunction;
- airway complications at the surgical connection;
- bleeding;
- blood clots;
- cardiovascular complications;
- kidney injury or chronic kidney dysfunction;
- medication-related adverse effects;
- acute cellular or antibody-mediated rejection;
- chronic lung allograft dysfunction;
- opportunistic infections; and
- increased risk of certain cancers associated with long-term immunosuppression.
These risks explain why transplantation is reserved for patients in whom the expected benefit justifies the burden of the operation and lifelong follow-up.
Rejection
The immune system is designed to recognize and attack material it identifies as foreign. A transplanted lung comes from another person, so the recipient’s immune system may attack the donor organ.
Immunosuppressive therapy reduces this risk but does not eliminate it.
Rejection can occur in different forms and at different times after transplantation. Some episodes can be treated, while chronic allograft dysfunction remains a major limitation to long-term survival.
Infection
The same medicines that suppress rejection also weaken parts of the body’s immune defenses. This creates an unavoidable clinical balancing act: too little immunosuppression increases rejection risk, while excessive immunosuppression increases susceptibility to serious infection and other complications.
Transplant recipients therefore require lifelong specialist monitoring rather than only a short period of postoperative follow-up.
Symptoms After Lung Transplant That Require Medical Attention
Recovery from lung transplantation is closely supervised. New symptoms should be reported according to the transplant team’s instructions because rejection, infection, medication toxicity, and other complications can overlap.
Potential warning signs may include:
- new or worsening shortness of breath;
- persistent cough;
- fever or chills;
- unusual fatigue or weakness;
- reduced exercise tolerance;
- chest discomfort;
- changes in oxygen levels;
- changes in lung function measurements; or
- unexplained weight changes.
These symptoms are not specific enough to diagnose rejection at home. A cough or shortness of breath, for example, could have several possible causes.
A transplant team may use pulmonary function testing, imaging, laboratory studies, bronchoscopy, biopsy, and other assessments depending on the suspected complication. Symptoms after transplantation should be evaluated through the patient’s transplant program rather than self-diagnosed.
Recovery and Life After Lung Transplantation
A successful transplant operation is the beginning of long-term treatment, not the end of it.
Immediately after surgery, patients are closely monitored for organ function, bleeding, infection, and other early complications. Rehabilitation begins as the patient becomes medically stable, with the goal of rebuilding strength and improving functional capacity.
After discharge, follow-up remains intensive. Patients need regular clinical assessment, laboratory testing, monitoring of lung function, and medication adjustment.
Lifelong immunosuppressive therapy is required to reduce the risk of rejection. Specific drug combinations vary by patient and transplant center. Because these medications can have significant adverse effects and interactions, treatment must be managed by the transplant team rather than adjusted independently.
Recovery speed varies considerably. It is more useful to think of rehabilitation as an individualized process extending over months rather than as a fixed six-month recovery period that applies to every recipient.
Lung Transplant Prognosis and Survival
Modern U.S. transplant outcomes are better than the older estimate that only 40% to 50% of recipients survive four or five years.
The OPTN/SRTR 2023 Annual Data Report states that among U.S. lung transplant recipients transplanted from 2016 through 2018, patient survival was approximately 89% at one year and 60.1% at five years. Outcomes vary according to factors including recipient characteristics, underlying diagnosis, transplant type, complications, and other clinical factors.
These figures describe lung transplant recipients overall. They should not be interpreted as survival estimates for mesothelioma patients receiving lung transplants, because transplantation is not an established standard treatment for active malignant pleural mesothelioma.
Mesothelioma prognosis is a separate question. It depends on factors such as disease extent, histologic subtype, whether the cancer can be treated surgically, overall health, response to therapy, and other individual clinical characteristics.
What Treatments Are Used for Pleural Mesothelioma Instead?
Because lung transplantation is generally not a standard option for active mesothelioma, treatment planning should focus on established cancer-directed and symptom-directed approaches.
The National Cancer Institute identifies treatment modalities that include:
- surgery for appropriately selected patients;
- chemotherapy;
- immunotherapy;
- radiation therapy;
- targeted therapy in relevant settings; and
- participation in clinical trials when appropriate.
Treatment selection is not determined by one factor alone. A multidisciplinary mesothelioma team may consider disease stage and distribution, histology, molecular findings when relevant, cardiopulmonary reserve, previous treatments, symptoms, overall health, and the patient’s goals.
Symptom management is also an important part of care. Pleural disease can cause shortness of breath, chest pain, cough, and recurrent pleural fluid accumulation. Management may include procedures and supportive treatments aimed at improving breathing and comfort alongside cancer-directed therapy.
Questions to Ask a Mesothelioma Specialist
When severe breathing problems are present, it is reasonable to ask whether every available surgical option has been considered. The most useful discussion, however, is one grounded in the biology and extent of the cancer.
Questions worth discussing with the treatment team include:
- Is my mesothelioma considered resectable?
- What is the histologic subtype of my tumor?
- What are the goals of the recommended treatment?
- Am I a candidate for surgery as part of a multimodality treatment plan?
- What systemic therapy options are appropriate for my disease?
- Are relevant clinical trials available?
- Which treatments could improve symptoms such as shortness of breath or pleural fluid accumulation?
- Would a second opinion at a high-volume mesothelioma center change my options?
For most people with active malignant pleural mesothelioma, the treatment pathway leads toward specialized cancer care rather than routine lung transplantation. That distinction is not merely technical: mesothelioma involves tissue surrounding the lung, and replacing the lung does not automatically remove the disease.
A consultation with a multidisciplinary mesothelioma team can clarify which established treatments, surgical approaches, systemic therapies, clinical trials, and supportive interventions are realistic for an individual case.
- About the Author
- Latest Posts
Salwa Alifah Yusrina is the Editor-in-Chief at Medslat.com. She is a professional Nutritionist with over 7 years of clinical and research experience. She holds a Master’s degree in Nutrition Science from Hasanuddin University. At Medslat.com, she oversees the editorial direction and ensures that all health and nutrition content adheres to the highest standards of accuracy and evidence-based science.
